J.Safra Asset Management Corp Summit Therapeutics Inc. Transaction History
J.Safra Asset Management Corp
- $1.31 Billion
- Q2 2025
A detailed history of J.Safra Asset Management Corp transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, J.Safra Asset Management Corp holds 13 shares of SMMT stock, worth $362. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13Holding current value
$362% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
238Shares Held
87.3MCall Options Held
1.77MPut Options Held
2.48M-
Baker Bros. Advisors LP New York, NY24.4MShares$681 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$325 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$220 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$183 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$135 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.61B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...